1. Generics Bulletin
  2. >>Products
  3. >>Generics

Sanders Mulls Generic Possibilities As He Blasts Novo Over High Ozempic And Wegovy Prices

Suggests Generics Could Sell For $100 A Month; Novo CEO Open To Potential Talks With PBMs

 
• By Adam Zamecnik

In a closely anticipated US Senate Committee hearing, Novo’s CEO was grilled by US senator Bernie Sanders and others on the high price of Ozempic and Wegovy in the country.

Senate seal photograph
• Source: Shutterstock

Senator Bernie Sanders has blasted Novo Nordisk’s CEO Lars Fruergaard Jørgensen over the high cost of Ozempic and Wegovy in the US in a 24 September Senate hearing, with Jørgensen stating that the firm was open to potential talks with pharmacy benefit managers after Sanders suggested that generic rivals could step in at a much lower price.

In his opening remarks, Sanders argued that Novo Nordisk had significantly overcharged US patients in need of Ozempic and Wegovy even

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.